774: USE OF DROXIDOPA FOR HEMODYNAMIC SUPPORT AND VASOPRESSOR WEANING IN THE INTENSIVE CARE UNIT
Critical Care Medicine, 2022 Melissa Noble +2 more
openalex +2 more sources
Neurogenic orthostatic hypotension – management update and role of droxidopa
Therapeutics and Clinical Risk Management, 2015 Orthostatic hypotension (OH) is defined as a significant decrease in blood pressure (BP) during the first 3 minutes of standing or a head up on a tilt table. Symptoms of OH are highly variable, ranging from mild light-headedness to recurrent syncope.
Vijay K. Sharma, Joy Vijayan
openalex +5 more sources
Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension [PDF]
European Heart Journal, 2018 Satish R. Raj, L. Arthur Hewitt
openalex +4 more sources
POS-800 DROXIDOPA FOR MANAGEMENT OF CHRONIC HYPOTENSION IN HAEMODIALYSIS [PDF]
Kidney International Reports, 2021 A. Jayanti +4 more
doaj +3 more sources
Financial Conflicts of Interest During Meetings of the Cardiovascular and Renal Drugs Advisory Committee [PDF]
, 2022 Context: The Cardiovascular and Renal Drugs Advisory Committee (CRDAC) of the Food and Drug Administration (FDA) reviews safety and efficacy data for cardiovascular and renal drugs, ultimately making recommendations to the Commissioner of Food and Drugs ...
Ahlander, Joseph +7 more
core +2 more sources
Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease [PDF]
Clinical Autonomic Research, 2017 Brent P. Goodman +2 more
openalex +2 more sources
Molecular Informatics, Volume 42, Issue 12, December 2023., 2023 Abstract Agonists of the β2 adrenergic receptor (ADRB2) are an important class of medications used for the treatment of respiratory diseases. They can be classified as short acting (SABA) or long acting (LABA), with each class playing a different role in patient management.
Luca Chiesa +2 more
wiley +1 more source
Cardiorespiratory dysautonomia in post‐COVID‐19 condition: Manifestations, mechanisms and management
Journal of Internal Medicine, Volume 294, Issue 5, Page 548-562, November 2023., 2023 Abstract A significant proportion of COVID‐19 patients experience debilitating symptoms for months after the acute infection. According to recent estimates, approximately 1 out of 10 COVID‐19 convalescents reports persistent health issues more than 3 months after initial recovery.
Artur Fedorowski +6 more
wiley +1 more source
Prospects for Droxidopa in Neurogenic Orthostatic Hypotension [PDF]
Hypertension, 2015 See related article, pp 101–107 Neurogenic orthostatic hypotension (nOH) is a debilitating disorder defined by a sustained decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within 3 minutes of head-up tilt or standing.1 The disorder is associated with attenuated increases in plasma norepinephrine and peripheral
Julian M. Stewart, Amanda J. Ross
openaire +3 more sources
Prevention of Falls in Parkinson's Disease: Guidelines and Gaps
Movement Disorders Clinical Practice, Volume 10, Issue 10, Page 1459-1469, October 2023., 2023 ABSTRACT Background People living with Parkinson's disease (PD) have a high risk for falls. Objective To examine gaps in falls prevention targeting people with PD as part of the Task Force on Global Guidelines for Falls in Older Adults. Methods A Delphi consensus process was used to identify specific recommendations for falls in PD.
Richard Camicioli +7 more
wiley +1 more source